Prophylactic vs. therapeutic enoxaparin in severe COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20220412054515N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

COVID-19 infection diagnosed by PCR
Hospitalization requirement
Having at least two signs of severe COVID-19 infection: (1) respiratory rate>30 (2) Spo2<93% (3) Pao2/Fio2<300 (4) progression in CT scan imaging>50% in 48 hours

Exclusion Criteria

Pregnancy
History of CVA in last month
History of major surgery in last two weeks
History of heparin induced thrombocytopenia
Other definitive indications for therapeutic enoxaparin treatment
Any contraindication for enoxaparin treatment

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cumulative 6-month survival. Timepoint: 6 months after admission. Method of measurement: Visit or phonecall.

Secondary Outcome Measures

Name	Time	Method
Hospitalization duration (days). Timepoint: After discharge or death. Method of measurement: Patient files.;Need for Intensive Care Unit admission. Timepoint: After discharge or death. Method of measurement: Patient files.;Need for mechanical ventilation. Timepoint: After discharge or death of patient. Method of measurement: Patient files.;Major bleeding defined by International Society on Thrombosis and Haemostasis criteria. Timepoint: After discharge or death. Method of measurement: Patient files.